Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
DYN 
Dyne Therapeutics Inc (DYN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DYN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 134.85% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.12B USD | Price to earnings Ratio - | 1Y Target Price 48.21 |
Price to earnings Ratio - | 1Y Target Price 48.21 | ||
Volume (30-day avg) 1710104 | Beta 1.11 | 52 Weeks Range 8.94 - 47.45 | Updated Date 04/2/2025 |
52 Weeks Range 8.94 - 47.45 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.37 |
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.912 | Actual -0.88 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.2% | Return on Equity (TTM) -88.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 425830125 | Price to Sales(TTM) - |
Enterprise Value 425830125 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.87 | Shares Outstanding 113121000 | Shares Floating 97275317 |
Shares Outstanding 113121000 | Shares Floating 97275317 | ||
Percent Insiders 0.69 | Percent Institutions 100.8 |
Analyst Ratings
Rating 4.5 | Target Price 50.83 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dyne Therapeutics Inc
Company Overview
History and Background
Dyne Therapeutics, Inc. was founded in 2017. It is a clinical-stage biotechnology company focused on developing therapies for serious muscle diseases.
Core Business Areas
- Muscle Disease Therapies: Dyne focuses on developing therapies for Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy Type 1 (DM1), and Facioscapulohumeral Muscular Dystrophy (FSHD).
Leadership and Structure
Dyne Therapeutics is led by CEO John Cox. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- DYNE-251 (DMD): DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a Fragment antigen-binding (Fab) to target exon 51 skipping for DMD patients. It's in clinical trials. Competitors include Sarepta Therapeutics (SRP) and NS Pharma.
- DYNE-101 (DM1): DYNE-101 is an antisense oligonucleotide (ASO) conjugated to a Fab to target DM1 patients. It's in clinical trials. Competitors include Ionis Pharmaceuticals (IONS).
- DYNE-301 (FSHD): DYNE-301 is targeting FSHD and is in pre-clinical development.
Market Dynamics
Industry Overview
The industry focuses on developing therapies for rare genetic diseases, which is characterized by high unmet medical need and potential for orphan drug designation.
Positioning
Dyne is positioning itself as a leader in targeted oligonucleotide therapeutics for muscle diseases using its FORCE platform.
Total Addressable Market (TAM)
The total addressable market for DMD, DM1, and FSHD is estimated to be several billion dollars. Dyne is targeting specific patient populations within these diseases.
Upturn SWOT Analysis
Strengths
- Novel FORCE platform for targeted oligonucleotide delivery
- Pipeline focused on large, genetically defined muscle diseases
- Experienced management team
Weaknesses
- Clinical trial risk
- Reliance on FORCE platform success
- High cash burn rate
Opportunities
- Expansion of FORCE platform to other diseases
- Potential for strategic partnerships
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure in clinical trials
Competitors and Market Share
Key Competitors
- SRPT
- IONS
- PTCT
Competitive Landscape
Dyne Therapeutics is competing with established players in the rare disease space. Dyne's FORCE platform offers a unique approach to targeted oligonucleotide delivery, but they face competition from other modalities and established market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by advancing its pipeline through preclinical and clinical development.
Future Projections: Future growth depends on clinical trial outcomes and potential regulatory approvals.
Recent Initiatives: Advancing DYNE-251 and DYNE-101 through clinical trials, and progressing DYNE-301 into clinical studies.
Summary
Dyne Therapeutics is a clinical-stage biotech company focused on developing therapies for serious muscle diseases. Its FORCE platform represents a promising approach for targeted drug delivery, but the company faces significant clinical trial risk. Positive trial results could drive substantial growth, while setbacks could negatively impact the stock. The company also has a high cash burn rate as they further develop their pipeline.
Similar Companies
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
SRPT
Sarepta Therapeutics Inc
SRPT
Sarepta Therapeutics Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share is estimated and may vary based on disease segment and product.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyne Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-17 | CEO, President & Director Mr. John G. Cox M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 191 | Website https://www.dyne-tx.com |
Full time employees 191 | Website https://www.dyne-tx.com | ||
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.